Ludger Grosse-Hovest

As a biologist with a doctorate in the field of immunology, Dr. Ludger Grosse-Hovest for more than 25 years with recombinant therapeutic antibodies for cancer treatment and also with the development of new antibody formats. Until 2012 he was a group leader at the Institute for Immunology at the Eberhard-Karls University in Tübingen. Building on an award and funding received from the German Federal Ministry of Education and Research (BMBF), he co-founded the biotechnology company Synimmune GmbH in 2012, in which he has been responsible for scientific management and management to this day.